Kratom News logo
Kratom NEWS graphic reading AKA Files an MGPI Lawsuit Over Trace Level Chemistry, citing case 1:26-cv-02997
The American Kratom Association filed suit in Washington on Aug. 27, 2026. Graphic: kratom.news

WASHINGTON — Two days after the Justice Department announced emergency Schedule I control of three potent kratom-related opioid compounds, the American Kratom Association took the fight over what that order actually covers to federal court. The MGPI lawsuit, filed Aug. 27 in the U.S. District Court for the District of Columbia as Case No. 1:26-cv-02997, does not try to undo the scheduling action. It asks a judge to write down, in enforceable terms, the limit the government has already described in its own press release.

THE ORDER AT A GLANCE
3
compounds scheduled: MGPI, MGM-15, MGM-16
2 yrs
the temporary order’s stated term
0.05%
threshold DEA proposed in its separate 7-OH action

🏛️ What the MGPI Lawsuit Actually Asks For

The complaint names the Drug Enforcement Administration, DEA Administrator Terrance C. Cole and the Department of Justice as defendants. Its central request is narrow: a declaration that the temporary scheduling order does not reach traditional botanical kratom products whose only pseudoindoxyl content is naturally occurring, naturally formed, or present in trace quantities — with no intentional synthesis, isolation, enrichment, fortification, concentration or addition.

If the government disagrees and argues the order does sweep in botanical leaf, the AKA asks the court in the alternative to set aside or enjoin that application and require DEA to articulate a reasoned, scientifically defensible standard first. That is a conventional administrative-law posture, not an attack on the scheduling power itself.

The association has been explicit that it is not defending concentrated products. It supported the DEA order when it landed and says its GMP participants neither make nor sell products intentionally fortified with pseudoindoxyl.

“The AKA supports aggressive enforcement against chemically manipulated MGPI, MGM-15, and MGM-16 products. But responsible kratom consumers and legitimate botanical kratom businesses should not be put at risk because trace-level chemistry is detected in otherwise traditional botanical kratom.”
— Mac Haddow, Senior Fellow on Public Policy, American Kratom Association

⚖️ The Gap Between the Press Release and the Order

Infographic showing three emergency-scheduled compounds, a two-year order term, and the 0.05 percent 7-OH threshold DEA proposed
Graphic: kratom.news

The Justice Department’s Aug. 25 announcement is unusually clear about scope. It states the action “is directed at deliberately manufactured and concentrated opioid products, not traditional botanical kratom,” and acknowledges that published literature has not established MGPI as a naturally occurring kratom alkaloid — while conceding open questions about whether it may be reported at incidental trace levels because of processing, storage or analytical conditions.

On that basis DOJ said it will exercise enforcement discretion when only incidental trace amounts of MGPI turn up in a product otherwise consistent with botanical kratom. The department was equally clear about the limits of that promise: it “does not create a legal exemption and does not change MGPI’s status as a schedule I controlled substance,” and it does not extend to MGM-15, MGM-16, or anything with added or concentrated MGPI.

That is the gap the MGPI lawsuit is aimed at. The enforcement-discretion language lives in the press release, not in the temporary order itself — a distinction Haddow flagged publicly before the filing. Prosecutorial discretion is also revocable by the next set of officials, which is precisely why a declaratory judgment is worth more to the industry than a paragraph in a news advisory.

🔬 Why Trace Chemistry Became the Fight

The chemistry here is genuinely unsettled, and the honest version is not flattering to either side’s talking points. Mitragynine, 7-hydroxymitragynine and pseudoindoxyl are structurally related, and the complaint argues trace pseudoindoxyl can form through ordinary post-harvest handling, storage or even analytical conditions without anyone synthesizing anything. It cites accredited laboratory testing that found trace pseudoindoxyl in unprocessed leaf and botanical powder at levels far below the concentrated products that triggered the DEA action. DOJ, for its part, says the published literature has not established MGPI as a natural constituent.

Nobody has settled that question yet, which is the problem when a chemical listing carries no threshold. The AKA’s strongest argument is a comparison to DEA’s own work: in the companion 7-OH proposal, the agency recognized it needed a numeric line — 0.05% — to separate naturally occurring trace 7-OH from enhanced or synthetic product. No equivalent line exists for MGPI. As we reported when testing methods started catching up to the rules that depend on them, detection limits have fallen fast enough that a lab can now find what a regulator never meant to capture.

The perverse result, the complaint argues, is that the quality-control testing consumer-protection laws require could itself generate the evidence for an enforcement case. University of Florida pharmacy professor Christopher McCurdy, who co-authored recent work on widespread mislabeling of kratom-derived products, has raised a related concern from the research side: Schedule I status makes legitimate study of these compounds substantially harder, and may push an unregulated market further into the shadows.

🌐 What Changes for Consumers, Vendors and Labs

Practically, nothing about the order changed on Aug. 27. MGPI, MGM-15 and MGM-16 remain Schedule I for a stated two-year term. Products built around them are gone from the legal market — Kansas City-based CBD American Shaman, which says it produced most of the nation’s MGPI supply, told the Missouri Independent it destroyed roughly $10 million of inventory at cost ahead of the order.

For consumers buying plain leaf and powder, the federal government’s stated position is that they are not the target. That is a meaningful statement, and it is also not the same thing as a rule. Anyone shopping should still expect vendors to hold current certificates of analysis; our Kratom Vendors directory tracks who publishes them. State law remains the sharper constraint for most people: kratom is banned outright in eleven states, and Massachusetts placed every form in Schedule I on Aug. 28 under an emergency public-health order.

A necessary caution regardless of where the litigation lands: kratom is not risk-free. Regular use can produce physical dependence and a withdrawal syndrome, and combining it with opioids, benzodiazepines or alcohol raises the risk of serious harm. Legal status and safety are separate questions, and a favorable ruling for the AKA would not alter the second one.

📋 What to Watch Next

Three things will shape the next month. First, whether DOJ responds to the MGPI lawsuit by conceding the botanical carve-out — which would resolve it quickly — or by defending the order’s literal breadth, which would force the court to weigh in. Second, the still-unissued 7-OH scheduling order, which is where the 0.05% threshold question gets decided for the much larger 7-OH market. Third, Sen. Ron Wyden’s Finance Committee inquiry into potential conflicts of interest behind the administration’s 7-OH push, with a document deadline at the end of this month.

State legislatures are moving on their own clock. North Dakota lawmakers convene Sept. 2 to decide whether to codify a total ban or replace it with a regulatory framework — a choice that will look different depending on how clearly the federal line ends up drawn.

❓ Frequently Asked Questions

What is the AKA MGPI lawsuit?

It is a civil action filed Aug. 27, 2026 by the American Kratom Association in the U.S. District Court for the District of Columbia, Case No. 1:26-cv-02997. It seeks declaratory and injunctive relief confirming that the DEA temporary scheduling order for MGPI, MGM-15 and MGM-16 does not apply to traditional botanical kratom that contains only incidental or naturally formed trace amounts of pseudoindoxyl.

Does the lawsuit try to overturn the DEA scheduling order?

No. The complaint expressly does not ask the court to invalidate the order in the first instance. The AKA says it supports federal control of intentionally synthesized, concentrated or fortified MGPI products, and is asking only that the order not be read to reach natural leaf.

Is botanical kratom leaf now a Schedule I substance federally?

The Justice Department states the action targets deliberately manufactured and concentrated opioid products, not traditional botanical kratom, and says it will exercise enforcement discretion where only incidental trace MGPI is confirmed. DOJ also says that policy is not a legal exemption. Kratom leaf itself has not been federally scheduled, but eleven states ban it under state law.

What are MGPI, MGM-15 and MGM-16?

They are potent mu-opioid receptor agonists chemically related to mitragynine and 7-hydroxymitragynine. DEA describes them as chemical rearrangements or derivatives of 7-OH. Products containing MGPI first appeared on the market in 2024 and MGM-15 about a year later; MGM-16 has not been confirmed in the consumer market.

How long does the temporary scheduling order last?

The order remains in effect for two years, with the possibility of extension while permanent scheduling is considered. The separate 7-OH scheduling order DEA proposed has not yet been issued.

📚 Sources

Not medical advice. This article is journalism about law and policy, not medical, legal or health guidance. Kratom is not approved by the FDA for any medical use. Regular use can cause physical dependence and withdrawal, and combining kratom with opioids, benzodiazepines or alcohol increases the risk of serious harm. Talk to a qualified clinician before starting or stopping any substance, and check your current state and local law — it changes often.